All In Biotech

Drug Trial Radar · NCT01654146

ICON8: Weekly Chemotherapy in Ovarian Cancer

An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Last checked: Nov 20, 2026Latest source record: Jul 31, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,485 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,485

Planned (sponsor's estimate)

Start

Jun 2011

Primary completion

Jun 2017

Sponsor

Lead sponsor
Medical Research CouncilGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Cancer Research UK
First posted
Jul 31, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if weekly chemotherapy (i.e. giving paclitaxel or carboplatin at a lower dose every week) is more effective than standard chemotherapy (paclitaxel and carboplatin given once every three weeks over 18 weeks) in treating ovarian cancer. The investigators also want to see if weekly chemotherapy causes more or fewer side-effects than standard chemotherapy.

Conditions

  • Ovarian Cancer

Interventions

  • CarboplatinDrug

    AUC5 by intravenous infusion over 30-60 minutes

  • CarboplatinDrug

    AUC2 by intravenous infusion over 30-60 minutes

  • PaclitaxelDrug

    175mg/m2 by intravenous infusion over 3 hours

  • PaclitaxelDrug

    80mg/m2 by intravenous infusion over 1 hour

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Feasibility assessed as the number of cycles and dose intensity of protocol treatment delivered per patient.Time frame: 6 months after the 50th patient has been randomised to each arm and 6 months after the 50th patient with a plan to undergo delayed primary surgery has been randomised to each arm
  2. Stage 1: Safety assessed as the rate of any ≥ grade 3 toxicity experienced per patient.Time frame: 6 months after the 50th patient has been randomised to each arm and 6 months after the 50th patient with a plan to undergo delayed primary surgery has been randomised to each arm
  3. Stage 2: Progression Free Survival rate at 9 months after randomisationTime frame: 9 months after first 62 patients randomised per arm
  4. Stage 3: Progression Free SurvivalTime frame: PFS expected 1 year after last patient is randomised. OS expected 3 years after last patient is randomised.
  5. Stage 3: Overall SurvivalTime frame: PFS expected 1 year after last patient is randomised. OS expected 3 years after last patient is randomised.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Research Council Clinical Trials Unit

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.